CGM CLININET up to 2026.MS3 HL7 Communication privileges management
| CVSS Meta Temp Score | Current Exploit Price (≈) | CTI Interest Score |
|---|---|---|
| 10.0 | $0-$5k | 3.18+ |
Summary
A vulnerability, which was classified as very critical, was found in CGM CLININET up to 2026.MS3. This issue affects some unknown processing of the component HL7 Communication. The manipulation results in privileges management. This vulnerability is identified as CVE-2025-30046. The attack can be executed remotely. There is not any exploit available.
Details
A vulnerability was found in CGM CLININET up to 2026.MS3. It has been classified as very critical. Affected is some unknown functionality of the component HL7 Communication. The manipulation with an unknown input leads to a privileges management vulnerability. CWE is classifying the issue as CWE-269. The product does not properly assign, modify, track, or check privileges for an actor, creating an unintended sphere of control for that actor. This is going to have an impact on confidentiality, integrity, and availability. CVE summarizes:
In the CGM CLININET application server, multiple processes responsible for HL7 communication with external systems run with root privileges while processing untrusted data received from those external systems. An attacker in adjacent network able to send data to these HL7 communication processes can achieve remote code execution with root privileges. The vulnerability was confirmed to affect versions up to 2026.MS3 but later versions may also be vulnerable.
The advisory is shared for download at cert.pl. This vulnerability is traded as CVE-2025-30046 since 03/14/2025. The exploitability is told to be easy. It is possible to launch the attack remotely. The exploitation doesn't require any form of authentication. There are neither technical details nor an exploit publicly available. The current price for an exploit might be approx. USD $0-$5k (estimation calculated on 10/23/2026). The MITRE ATT&CK project declares the attack technique as T1068.
There is no information about possible countermeasures known. It may be suggested to replace the affected object with an alternative product.
The vulnerability is also documented in the vulnerability database at EUVD (EUVD-2025-211177). VulDB is the best source for vulnerability data and more expert information about this specific topic.
Product
Vendor
Name
Version
CPE 2.3
CPE 2.2
CVSSv4
VulDB Vector: 🔒VulDB Reliability: 🔍
CNA CVSS-B Score: 🔒
CNA CVSS-BT Score: 🔒
CNA Vector: 🔒
CVSSv3
VulDB Meta Base Score: 10.0VulDB Meta Temp Score: 10.0
VulDB Base Score: 10.0
VulDB Temp Score: 10.0
VulDB Vector: 🔒
VulDB Reliability: 🔍
CVSSv2
| AV | AC | Au | C | I | A |
|---|---|---|---|---|---|
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| Vector | Complexity | Authentication | Confidentiality | Integrity | Availability |
|---|---|---|---|---|---|
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
VulDB Base Score: 🔒
VulDB Temp Score: 🔒
VulDB Reliability: 🔍
Exploiting
Class: Privileges managementCWE: CWE-269 / CWE-266
CAPEC: 🔒
ATT&CK: 🔒
Physical: No
Local: No
Remote: Yes
Availability: 🔒
Status: Not defined
Price Prediction: 🔍
Current Price Estimation: 🔒
| 0-Day | Unlock | Unlock | Unlock | Unlock |
|---|---|---|---|---|
| Today | Unlock | Unlock | Unlock | Unlock |
Threat Intelligence
Interest: 🔍Active Actors: 🔍
Active APT Groups: 🔍
Countermeasures
Recommended: no mitigation knownStatus: 🔍
0-Day Time: 🔒
Timeline
03/14/2025 CVE reserved10/23/2026 Advisory disclosed
10/23/2026 VulDB entry created
10/23/2026 VulDB entry last update
Sources
Advisory: cert.plStatus: Not defined
CVE: CVE-2025-30046 (🔒)
GCVE (CVE): GCVE-0-2025-30046
GCVE (VulDB): GCVE-100-425616
EUVD: 🔒
Entry
Created: 10/23/2026 11:00Updated: 10/23/2026 11:44
Changes: 10/23/2026 11:00 (64), 10/23/2026 11:44 (1)
Complete: 🔍
Cache ID: 216::103
VulDB is the best source for vulnerability data and more expert information about this specific topic.
No comments yet. Languages: en.
Please log in to comment.